All In Biotech

Drug Trial Radar · NCT03888053

BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Topical BB-101 (rhNEGF) for the Treatment of Diabetic Lower Leg and Foot Ulcers

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Mar 28, 2018

Primary completion

Dec 1, 2021

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Blue Blood Biotech Corp.Industry
Sponsor type
Industry
First posted
Mar 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, sequential dose escalation study in diabetic subjects with a diabetic lower leg or foot ulcer. All subjects will receive standard-of-care ulcer treatment from screening through the last study visit.

Conditions

  • Diabetic Foot Ulcer

Interventions

  • BB-101Biological

    Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of local reactionsTime frame: 6 weeks
  2. Incidence and severity of adverse eventsTime frame: 6 weeks
  3. Incidence of clinical laboratory abnormalitiesTime frame: 6 weeks
  4. Change from baseline in ECGTime frame: 6 weeks
  5. Change from baseline in blood pressureTime frame: 6 weeks
  6. Change from baseline in heart rateTime frame: 6 weeks
  7. Change from baseline in body temperatureTime frame: 6 weeks
  8. Presence of anti-BB-101 antibodiesTime frame: 6 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • E-DA Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Shuangho Hospital

    New Taipei City, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Shin Kong Wu Ho-Su Memorial Hospital

    Taipei, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.